Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands (Q38441105)

3 September 2017

Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands (English)

1 reference

3 September 2017

0 references

1 reference

Heleen G M van Haalen

1

1 reference

3 September 2017

Marjolein Pompen

2

1 reference

3 September 2017

Klas Bergenheim

3

1 reference

3 September 2017

Phil McEwan

4

1 reference

3 September 2017

Rebecca Townsend

5

1 reference

3 September 2017

Marina Roudaut

6

1 reference

3 September 2017

1 February 2014

1 reference

Clinical Drug Investigation

3 September 2017

1 reference

3 September 2017

34

1 reference

3 September 2017

2

1 reference

3 September 2017

135-146

1 reference

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

3 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Insulin treatment and the problem of weight gain in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Intensification of therapy and no increase in body mass index with longer disease duration in type 2 diabetes mellitus (ZODIAC-5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Combination of insulin and metformin in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Cost of hypoglycemia in patients with Type 2 diabetes in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Estimating the cost of complications of diabetes in Australia using administrative health-care data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Atrial fibrillation: the cost of illness in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Utility loss and indirect costs after stroke in Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Return to work after lower limb amputation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Costs of vision impairment: present and future issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Long-term health and work outcomes of renal transplantation and patterns of work status during the end-stage renal disease trajectory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0155-0

Return to work after acute ST-segment elevation myocardial infarction in the modern era of reperfusion by direct percutaneous coronary intervention

21 January 2018

1 reference

12 December 2020

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

1 reference

12 December 2020

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

1 reference

12 December 2020

[Diabetes mellitus in the Netherlands: estimate of the current disease burden and prognosis for 2025]

1 reference

12 December 2020

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

1 reference

12 December 2020

Lifetime health effects and costs of diabetes treatment.

1 reference

12 December 2020

Diabetes: glycaemic control in type 2 (drug treatments).

1 reference

12 December 2020

Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study

1 reference

12 December 2020

Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies.

1 reference

12 December 2020

Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden

1 reference

12 December 2020

Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report

1 reference

12 December 2020

10.1007/S40261-013-0155-0

Identifiers

DOI

1 reference

3 September 2017

1 reference